By: DEBANGSHU S. ROY MBA P.M. Hamdard University
ABBREVIATED NEWDRUG APPLICATION
FILING
2
An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's CDER, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product.
Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low cost alternative to the public.
All approved products, both innovator and generic, are listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
ANDA
3
INNOVATOR VS GENERICS
S.N. PARAMETERS INNOVATOR DRUG GENERIC DRUG1. Active ingredients Same Same 2. Safety & efficacy Same Same 3. Quality & strength Same Same 4. Performance and standards Same Same 5. Costs/prescription Highly expensive Less expensive 6. FDA inspection of manufacturing facilities Yes Yes 7. FDA reviews reports of adverse reactions Yes Yes 8. FDA reviews drug labeling Yes No 9. Extensive research and development investments Yes No 10. Expensive marketing & advertising Yes No 11. Patent protection Yes No 12. FDA review to show active ingredient is equivalent to original NA Yes 13. Product Development Time ~ 12 yrs 2- 4 yrs
4
Generic Drug Approval
In 1970 FDA established the ANDA as a mechanism for the review and approval of generic versions.
Before 1978, generic product applicants were required to submit complete safety and efficacy through clinical trials.
Post 1978, applicants were required to submit published reports of such trials documenting safety and efficacy.
Neither of these approaches was considered satisfactory and so originated Hatch Waxman Act on 1984.
5
Indispensability GroundsFor Generics
Contain the same active ingredients as the innovator drug (inactive ingredients may vary).
Must be identical in strength, dosage form, and route of administration.
Must have same use/indications.
Must be bioequivalent.
Must have same batch requirements for Identity, Safety & Purity.
Must follow strict standards of FDA's GMPs.
6
Commonly known as “Drug Price Competition & Patent Term Restoration Act” of 1984.
“The Hatch-Waxman Act is an act dealing with the approval of generic drugs and associated conditions for getting their approval from FDA, market exclusivity, rights of exclusivity, patent term extension and Orange Book Listing.”Necessitated By :
1. Absence of Generic drug manufacturing. 2. Cumbersome regulatory procedures. 3. Patients were denied the option of cheaper drugs.
Hatch-Waxman Act
7
1. Maintaining list of patents which would be infringed.
2. Only Bioavailability studies and not clinical trials needed for approval.
3. Para I, II, III and IV certifications.
4. Data exclusivity period for New Molecular Entities.
5. Extension of the original patent term.
6. The “Bolar” Provision.
General Provisions of the Act
8
Recent additions to the Hatch-Waxman Act
Under the “Medicare Prescription Drug and Modernization Act”, 2003:
1.Non-extension of the 30-month period.
2.Time limit for informing patent owner.
3.Provision for allowing declaratory judgment.
4.Benefit of exclusivity for several ANDAs filed on same day allowed.
9
ANDA CERTIFICATION
CLAUSES
PARAGRAP
H I
PARAGRAPH II
PARAGRAPH III
PARAGRAPH IV
10
PARA-I
Required patent information has not been filed.
FDA may approve generics
immediately, one or more applicants
may enter.
PARA-II
Patent has expired
FDA may approve generics
immediately, one or more applicants
may enter.
11
PARA-III
Patent not expired, will be expired on
a specific date.
FDA may approved ANDA effective on
the date of expiration, one or
more applicant may enter.
PARA-IV
Patent is invalid or non infringed by
generic applicant.
Generic applicant file notice to
patent holder.
12
PARA IV CERTTIFICATION
After 45 days Patent Holder doesn’t sue
applicant ► FDA may approve ANDA.
ANDA Applicant granted approval.
After 45 days Patent Holder sues the Applicant ► 30months stay granted
to Patent Holder.
30 Months stay
expired
For the first Applicant the EMR of
180 day
s starts
with court’s decision
.
Subsequen
t approvals for
EMRs
are granted
after
expiry of
first applicant’s 180 days.
30 Months stay not expired.
13
30 Months stay not expired
If judgement’s in favour of Patent Holder ► FDA can not approve ANDA
untill patent expiry.
No entry occurs untill Patent
Expiry.
Judgement favouring ANDA ► EMR of 180 days begins for first
applicant.
First Applicant enters, subsequent applicants enter only after expiry
of EMR for the First Applicant.
14
APPLICANT
ANDA
ACCEPTABLE &COMPLETE
REFUSE TO FILE- LETTER ISSUED
B.E. REVIEW
REQUEST FOR PLANT INSPECTION
CHEMISTRY/MICRO REVIEW
LABELING REVIEW
NOT APPLICABLE LETTER
ANDA APPROVED
B.E. DEFICIENCY LETTER
APPROVAL DEFERRED PENDING SATISFACTORY RESULTS
PREAPPROVAL INSPECTION ACCEPTENCE
B.E. REVIEW ACCEPTABLE CHEMISTRY/LABELING REVIEW ACCEPTABLE
YES
YES
YES
NO
NO
NO
NO
ANDA REVIEW PROCESS
15
MODULE 1
MODULE 3 MODULE 4 MODULE 5
MO
DU
LE
2
Regional Admin.
Information
Quality
Overall
summary
Non Clinical overvie
wNon Clinical Summary
Clinical
Overview
Clinical Summary
Quality Non Clinical Report
Clinical Report
Not
part of
CTD
CTD
The CTD Triangle
16
MODULES IN A CTD
MODULE I: Administrative and Prescribing Information
1.Table of Contents.
2.Includes data of Administrative Documents entailing:Patent Information on patented product.Patent Certifications.Debarment certification.
3. Prescribing information like Package and container labels, packaging inserts, patient leaflets, etc.
4. Labelling Comparison between Innovator and Generic drug.
17
MODULE II: SUMMARIES AND OVERVIEWS
1. Table of Contents.
2. Introduction to Summary Documents.
3. Overviews and Summaries: Module II should contain documents like: M4Q: The CTD- quality M4S: The CTD- safety M4E: The CTD- efficacy MODULE III: information on product quality
1. Table of Content.
2. Body of Data.
3. Literature Reference.
18
MODULE IV: NON CLINICAL STUDY REPORTS
Not required in ANDA Filing.
MODULE V: CLINICAL STUDY REPORTS
1. Table of Contents.
2. Study Reports including Case Report Forms and Case Report Tabulations.
19
RECOMMENDATIONS FOR e-CTD
1. PDF Files with version 3.0 of Acrobat Reader
2. Use of Embedded fonts in the Portable Document Format
3. A Print area of 8.5 inches by 11 inches and margin of 1 inches is ensured on sides.
4. Scanned Documents should be avoided as Source Documents.
5. Hypertexts can be indicated by Blue-Texts or by rectangles using thin lines.
20
6. Numbering on the PDF and Documents should be included as same.
7. Security or Passwords should not be included.
8. Full Indexes should be included.
9. Electronic Signatures may be added, Procedures are being employed for archival of the same.
21
BIOEQUIVALENCE
A Generic drug is considered to be bioequivalent to Brand drug if:
Rate & extent of absorption do not show a significant difference from RLD.
Two drugs are said to be Bioequivalent if their Bioavailability after administration in same dose are similar to a degree that there effects, with respect to safety & efficacy can be expected to be the same.
22
NDA REQUIREMENT ANDA REQUIREMENT
NDA Vs ANDA Review Process
23
First-Time Generic Drug Approvals - July 2011
Generic Drug Name
Generic Manufacturer
Brand Name Approval Date
FONDAPARINUX SODIUM INJECTION
DR. REDDY'S LABORATORIES LIMITED
ARIXTRA INJECTION
7/11/2011
ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS
TEVA PHARMACEUTICALS USA
UROXATRAL EXTENDED-RELEASE TABLETS
7/18/2011
ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS
SUN PHARMA GLOBAL FZE
UROXATRAL EXTENDED-RELEASE TABLETS
7/18/2011
PARICALCITOL INJECTION
SANDOZ CANADA, INC.
ZEMPLAR INJECTION
7/27/2011
METRONIDAZOLE GEL
TOLMAR INC. METROGEL 7/22/2011
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
THANK YOU
Top Related